4,901 trials
Human Immunodeficiency Virus Type 1 (HIV-1)
Primary: Maximum Observed Plasma Concentration (Cmax) of Atazanavir — 3832; 4104; 2585; 2941 ng/mL
Diabetes Mellitus, Type 2
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 0; 0; 1 participants
Impaired Liver Function
Primary: Maximum Blood Concentration (Cmax) — 827.5; 587.6; 1589.5; 974.0 ng/L
Uveitic Cystoid Macular Edema
Primary: Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. — 12.2 Change in ETDRS Letters — p=0.0015
Drug Interactions
Primary: Plasma AUC Ratio of Day 1 and Day 8 — 1.093; 1.029; 1.104; 1.914 Ratio of geometric means Day 8 to Day 1
Depression · Depressive State · Enuresis
Primary: AUClast and AUCinf — 91.35; 260.68; 109.74; 296.87 ng*hr/mL
Bacillus Anthracis (Anthrax) Infection
Primary: Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0) — 11; 17; 13…
Lung Diseases
Primary: Standing Balance - Sway Path — 1.57; 3.40; 1.65; 2.59 cm/s
Effects of Different Meals on the QT/QTc Interval · Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use · C-Peptide Effects on the QT/QTc Interval
Primary: The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin — 14.4; 11.6 ms — p=0.05
Healthy Volunteers
Primary: Amount of Testosterone on T-shirts — 7603 micrograms (µg)
Overactive Bladder
Primary: Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 7 on Tolterodine 4 mg and Placebo — 1.15; 0.94 Percentage change — p=0.008
Healthy
Primary: AUC0-72 of Linagliptin — 317.0; 319.2; 309.6; 304.9 nmol*h/L
Non Malignant Disorders · Immunodeficiencies · Congenital Marrow Failures
Primary: Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving…
Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 3; 3; 25; 5 participants
Non-Small Cell Lung Carcinoma (NSCLC)
Primary: Patients Affected by Treatment-related Morbidities — 12 participants